BBIO vs. HIMS
BBIO (BridgeBio Pharma, Inc.) and HIMS (Hims & Hers Health, Inc.) are both stocks. BBIO operates in Biotechnology (Healthcare), while HIMS operates in Household & Personal Products (Consumer Defensive). Over the past 5 years, BBIO returned 2.47%/yr vs 14.51%/yr for HIMS. At a 0.26 correlation, their price movements are largely independent.
Performance
BBIO vs. HIMS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BBIO achieves a -14.39% return, which is significantly higher than HIMS's -15.28% return.
BBIO
- 1D
- 2.50%
- 1M
- -5.09%
- YTD
- -14.39%
- 6M
- -11.69%
- 1Y
- 74.52%
- 3Y*
- 66.21%
- 5Y*
- 2.47%
- 10Y*
- —
HIMS
- 1D
- 0.00%
- 1M
- 0.88%
- YTD
- -15.28%
- 6M
- -25.79%
- 1Y
- -49.74%
- 3Y*
- 45.13%
- 5Y*
- 14.51%
- 10Y*
- —
BBIO vs. HIMS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
BBIO BridgeBio Pharma, Inc. | -14.39% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 102.88% | 35.28% |
HIMS Hims & Hers Health, Inc. | -15.28% | 34.28% | 171.69% | 38.85% | -2.14% | -55.14% | 47.47% | 1.02% |
Correlation
The correlation between BBIO and HIMS is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.22 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.23 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Sep 16, 2019 | 0.26 |
Fundamentals
BBIO:
$12.75B
HIMS:
$6.28B
BBIO:
-$3.76
HIMS:
-$0.05
BBIO:
22.36
HIMS:
2.85
BBIO:
$566.04M
HIMS:
$2.37B
BBIO:
$538.20M
HIMS:
$1.70B
BBIO:
-$602.24M
HIMS:
$16.04M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BBIO vs. HIMS — Risk / Return Rank
BBIO
HIMS
BBIO vs. HIMS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Hims & Hers Health, Inc. (HIMS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BBIO | HIMS | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.61 | -0.52 | +2.13 |
Sortino ratioReturn per unit of downside risk | 2.26 | -0.35 | +2.62 |
Omega ratioGain probability vs. loss probability | 1.30 | 0.96 | +0.35 |
Calmar ratioReturn relative to maximum drawdown | 3.70 | -0.64 | +4.34 |
Martin ratioReturn relative to average drawdown | 9.47 | -1.06 | +10.53 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| BBIO | HIMS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.61 | -0.52 | +2.13 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.03 | 0.18 | -0.15 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.16 | 0.22 | -0.06 |
Drawdowns
BBIO vs. HIMS - Drawdown Comparison
The maximum BBIO drawdown since its inception was -92.80%, which is greater than HIMS's maximum drawdown of -87.29%. Use the drawdown chart below to compare losses from any high point for BBIO and HIMS.
Loading charts...
Drawdown Indicators
| BBIO | HIMS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.80% | -87.29% | -5.51% |
Max Drawdown (1Y)Largest decline over 1 year | -20.25% | -78.06% | +57.81% |
Max Drawdown (3Y)Largest decline over 3 years | -49.08% | -78.88% | +29.80% |
Max Drawdown (5Y)Largest decline over 5 years | -91.89% | -79.74% | -12.15% |
Current DrawdownCurrent decline from peak | -18.06% | -59.98% | +41.92% |
Average DrawdownAverage peak-to-trough decline | -45.85% | -43.19% | -2.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.89% | 47.08% | -39.19% |
Volatility
BBIO vs. HIMS - Volatility Comparison
The current volatility for BridgeBio Pharma, Inc. (BBIO) is 11.77%, while Hims & Hers Health, Inc. (HIMS) has a volatility of 25.84%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than HIMS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BBIO | HIMS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.77% | 25.84% | -14.07% |
Volatility (6M)Calculated over the trailing 6-month period | 34.50% | 66.58% | -32.08% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.93% | 95.97% | -49.04% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 86.00% | 83.37% | +2.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.86% | 77.20% | +6.66% |
Dividends
BBIO vs. HIMS - Dividend Comparison
Neither BBIO nor HIMS has paid dividends to shareholders.
Financials
BBIO vs. HIMS - Financials Comparison
This section allows you to compare key financial metrics between BridgeBio Pharma, Inc. and Hims & Hers Health, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BBIO vs. HIMS - Profitability Comparison
BBIO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a gross profit of 178.39M and revenue of 180.60M. Therefore, the gross margin over that period was 98.8%.
HIMS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a gross profit of 396.79M and revenue of 608.10M. Therefore, the gross margin over that period was 65.3%.
BBIO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported an operating income of -105.96M and revenue of 180.60M, resulting in an operating margin of -58.7%.
HIMS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported an operating income of -78.32M and revenue of 608.10M, resulting in an operating margin of -12.9%.
BBIO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BridgeBio Pharma, Inc. reported a net income of -164.04M and revenue of 180.60M, resulting in a net margin of -90.8%.
HIMS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a net income of -92.12M and revenue of 608.10M, resulting in a net margin of -15.2%.
Frequently Asked Questions
BBIO and HIMS have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
HIMS has higher volatility (25.84%) compared to BBIO (11.77%). In terms of maximum drawdown, BBIO dropped -92.80% vs HIMS's -87.29%.
BBIO currently has the higher Sharpe Ratio (1.61 vs -0.52), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BBIO and HIMS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer